tbuckley/cabot-search huggingface dataset:
Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Authors: Wolfgang P. Fendler, Jeremie Calais, Matthias Eiber, Robert R. Flavell, Ashley Mishoe, Felix Y. Feng, Hao G. Nguyen, Robert E. Reiter, Matthew B. Rettig, Shozo Okamoto, Louise Emmett, Helle D. Zacho, Harun Ilhan, Axel Wetter, Christoph Rischpler, Heiko Schoder, Irene A. Burger, Jeannine Gartmann, Raven Smith, Eric J. Small, Roger Slavik, Peter R. Carroll, Ken Herrmann, Johannes Czernin, Thomas A. Hope
Journal: JAMA Oncology (2019)

In retrospective studies, 68Ga-PSMA-11 positron emission tomographic (PET) imaging improves detection of biochemically recurrent prostate cancer compared with conventional imaging.To assess 68Ga-PSMA-11 PET accuracy in a prospective multicenter trial.In this single-arm prospective trial conducted at University of California, San Francisco and University of California, Los Angeles, 635 patients with biochemically recurrent prostate cancer after prostatectomy (n = 262, 41%), radiation therapy (n = 169, 27%), or both (n = 204, 32%) underwent 68Ga-PSMA-11 PET. Presence of prostate cancer was recorded by 3 blinded readers on a per-patient and per-region base. Lesions were validated by histopathologic analysis and a composite reference standard.Endpoints were positive predictive value (PPV), detection rate, interreader reproducibility, and safety.A total of 635 men were enrolled with a median age of 69 years (range, 44-95 years). On a per-patient basis, PPV was 0.84 (95% CI, 0.75-0.90) by histopathologic validation (primary endpoint, n = 87) and 0.92 (95% CI, 0.88-0.95) by the composite reference standard (n = 217). 68Ga-PSMA-11 PET localized recurrent prostate cancer in 475 of 635 (75%) patients; detection rates significantly increased with prostate-specific antigen (PSA): 38% for <0.5 ng/mL (n = 136), 57% for 0.5 to <1.0 ng/mL (n = 79), 84% for 1.0 to <2.0 ng/mL (n = 89), 86% for 2.0 to <5.0 ng/mL (n = 158), and 97% for ≥5.0 ng/mL (n = 173, P < .001). Interreader reproducibility was substantial (Fleiss κ, 0.65-0.78). There were no serious adverse events associated with 68Ga-PSMA-11 administration. PET-directed focal therapy alone led to a PSA drop of 50% or more in 31 of 39 (80%) patients.Using blinded reads and independent lesion validation, we establish high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.ClinicalTrials.gov identifiers: NCT02940262 and NCT03353740.
A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma
Authors: Akio Saito, Atsushi Isoda, Takeshi Odajima, Mitsuhiro Itagaki, Go Yamamoto, Shotaro Hagiwara, Tatsuharu Ohno, Ayumi Fujimoto, Naohiro Sekiguchi, Kazutaka Sunami, Akihiko Yokohama, Mineo Kurokawa, Yutaka Tsukune, Hideyuki Nakazawa, Hiroyuki Takamatsu, Hideo Yagi, Shin-Ichi Fuchida, Shigeki Ito, Yoriko Harazaki, Reiko Watanabe, Michiaki Koike, Kanji Miyazaki, Kazuhito Suzuki, Hideto Tamura, Takae Kohara, Shuji Ozaki, Nobuhiko Nakamura, Yuichi Nakamura, Toshio Wakayama, Hiroki Sugimori, Hirokazu Murakami
Journal: Blood (2018)
Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
Authors: Colleen T. Harrington, Elena Sotillo, Aude Robert, Katharina E. Hayer, Agata M. Bogusz, James Psathas, Duonan Yu, Deanne Taylor, Chi V. Dang, Peter S. Klein, Michael D. Hogarty, Birgit Geoerger, Wafik S. El-Deiry, Joëlle Wiels, Andrei Thomas-Tikhonenko
Journal: Leukemia (2019)
Implications of the Parenteral Opioid Shortage for Prescription Patterns and Pain Control Among Hospitalized Patients With Cancer Referred to Palliative Care
Authors: Ali Haider, Yu Qian, Zhanni Lu, Syed Naqvi, Amy Zhuang, Akhila Reddy, Shalini Dalal, Joseph Arthur, Kimberson Tanco, Rony Dev, Janet Williams, Jimin Wu, Diane Liu, Eduardo Bruera
Journal: JAMA Oncology (2019)

The recent parenteral opioid shortage (POS) has potential implications for cancer-related pain management in hospitalized patients.This study compared changes in opioid prescriptions and clinically improved pain (CIP) among patients treated by an inpatient palliative care (PC) team before and after our institution first reported the POS.A cohort study of 386 eligible patients with cancer treated at a comprehensive cancer center 1 month before and after the announcement of the POS. We reviewed data from electronic health records, including patient demographics, opioid type, route of administration, and dose. Board-certified palliative care specialists assessed CIP at follow-up day 1.The announcement of the POS by the institution's pharmacy and therapeutics committee on February 8, 2018.The primary outcome was to measure the change in opioid prescription patterns of physicians, and the secondary outcome was to measure the proportion of patients who achieved CIP before and after announcement of the POS.Of 386 eligible patients, 196 were men (51%), 270 were white (70%), and the median age was 58 years (interquartile range, 46-67 years). Parenteral opioids were prescribed less frequently by the referring oncology teams after the POS (56 of 314 [18%]) vs before the POS (109 of 311 [35%]) (P < .001). The PC team also prescribed fewer parenteral opioids after the POS (96 of 336 [29%]) vs before the POS (159 of 338 [47%]) (P < .001). After the POS (vs before the POS), significantly fewer patients achieved CIP on follow-up day 1 (119 [62%] vs 144 [75%] of 193; P = .01). Multivariate analysis showed that before the POS, patients had an 89% higher chance of achieving CIP on follow-up day 1 (odds ratio, 1.89; 95% CI, 1.22-2.94; P = .005).There was a significant change in opioid prescription patterns associated with the POS. Furthermore, after the POS, fewer patients achieved CIP. These factors have potential implications for patient satisfaction and hospital length of stay.
Abstract 15955: Impact of an Automated Chest Compression Device on Team Communication During Simulated Cardiac Arrest Resuscitations - A Pilot Study
Authors: Matthew Gittinger, Sarah Brolliar, James A Grand, Graham Nichol, Rosemarie Fernandez
Journal: Circulation (2015)

Background: Communication and teamwork failures correlate with diagnostic errors and deviations from ACLS protocols during cardiac arrest (CA) resuscitation. High task workloads stress teams’ capacity and negatively impact team effectiveness. The LUCAS ® Chest Compression System (Physio-Control, Redmond, WA) is an automated chest compression device intended to reduce workload associated with chest compression delivery. Objective: To assess the impact of LUCAS on team communication and adherence to ACLS algorithms during a simulated CA resuscitation. Methods: Resuscitation teams (n=12) were randomly assigned to manual compressions (control) or LUCAS (intervention) during a simulated CA consisting of Phase 1, pre-arrest (Baseline), and Phase 2, ventricular fibrillation phase (Arrest). Phase 1 metrics included total team communication statements and 10 patient care actions. Phase 2 communication was measured as number of statements related to (a) CPR coordination, (b) compression performance, and (c) diagnosis. Phase 2 patient care metrics included (a) adherence to ACLS algorithm and (b) quality of compressions. Statistical analyses included descriptive statistics, paired t-test, and effect size (Hedge’s g). Results: In Phase 1 there was no difference in either communication or patient care outcomes. In Phase 2, teams in the intervention group (n=6) made more frequent statements focused on diagnosis (Hedge’s g = 1.88, t[df 10]=3.53, p=0.01) and fewer directed toward CPR coordination (Hedge’s g = -0.98, t[df 10] = -1.85, p = 0.1) and compression performance (Hedge’s g = -1.55, t[df 10]=-2.91, p = 0.02). Teams using the LUCAS had a 22.8% decrease (95% CI [-48.80, 3.24]) in delivery of poor quality chest compressions (Hedge’s g = 1.04, t[df 10] = -1.87, p=0.08) and fewer deviations in medication administration (Hedge’s g = -1.49, t[df 10] = -1.87, p=0.02) as compared to in the control group (n=6). Conclusions: In this small pilot study, use of an automated compression device was associated with an increase in team communication focused on diagnosis and improved adherence to ACLS algorithms. While not all outcomes reached statistical significance, the large effect sizes demonstrate practical significance. A larger study may reach statistical significance.
Abstract 14706: Novel Mathematical Method of Determining Ventilatory Anaerobic Threshold
Authors: Hirotaka Nishijima, Kazuo Kondo, Kazuyuki Kominami, Masatoshi Akino, Masayuki Sakurai
Journal: Circulation (2017)

Ventilatory anaerobic threshold (VAT) is commonly employed as a submaximal measure of exercise tolerance. However, it must be visually determined. We developed a novel approach to objective mathema...
Source of Increased Health Care Spending in the United States
Authors: Adam I. Biener, Sandra L. Decker, Fredrick Rohde
Journal: JAMA (2019)

Joseph L. Dieleman, PhD; Jackie Cao, MS; Abby Chapin, BA; Carina Chen, MA; Zhiyin Li, MS; Angela Liu, MPH; Cody Horst, MPH; Alexander Kaldjian, MS; Taylor Matyasz, MS; Kirstin Woody Scott, MPhil, PhD; Anthony L. Bui, MD, MPH; Madeline Campbell, BS; Herbert C. Duber, MD, MPH; Abe C. Dunn, PhD; Abraham D. Flaxman, PhD; Christina Fitzmaurice, MD; Mohsen Naghavi, MD, MPH, PhD; Nafis Sadat, MA; Peter Shieh, MS; Ellen Squires, MPH; Kai Yeung, PharmD, PhD; Christopher J. L. Murray, MD, DPhil
Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done
Authors: Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Journal: Clinical Gastroenterology and Hepatology (2019)
Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein
Authors: Wenyan Zou, Tinglin Pu, Weixi Feng, Ming Lu, Ying Zheng, Renhong Du, Ming Xiao, Gang Hu
Journal: Translational Neurodegeneration (2019)

Abnormal aggregation of brain α-synuclein is a central step in the pathogenesis of Parkinson's disease (PD), thus, it is reliable to promote the clearance of α-synuclein to prevent and treat PD. Recent studies have revealed an essential role of glymphatic system and meningeal lymphatic vessels in the clearance of brain macromolecules, however, their pathophysiological aspects remain elusive.Meningeal lymphatic drainage of 18-week-old A53T mice was blocked via ligating the deep cervical lymph nodes. Six weeks later, glymphatic functions and PD-like phenotypes were systemically analyzed.Glymphatic influx of cerebrospinal fluid tracer was reduced in A53T mice, accompanied with perivascular aggregation of α-synuclein and impaired polarization of aquaporin 4 expression in substantia nigra. Cervical lymphatic ligation aggravated glymphatic dysfunction of A53T mice, causing more severe accumulation of α-synuclein, glial activation, inflammation, dopaminergic neuronal loss and motor deficits.The results suggest that brain lymphatic clearance dysfunction may be an aggravating factor in PD pathology.
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Authors: Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji, Xiaohe Li, Nicholas Chien, Mike Wei, Eiichi Ogawa, Changqing Zhao, Xia Wu, Christopher D Stave, Linda Henry, Scott Barnett, Hirokazu Takahashi, Norihiro Furusyo, Yuichiro Eguchi, Yao-Chun Hsu, Teng-Yu Lee, Wanhua Ren, Chengyong Qin, Dae Won Jun, Hidenori Toyoda, Vincent Wai-Sun Wong, Ramsey Cheung, Qiang Zhu, Mindie H Nguyen
Journal: The Lancet. Gastroenterology & hepatology (2019)
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
Authors: Alexandra D Frolkis, Isabelle A Vallerand, Scott B Patten, Gilaad G Kaplan
Journal: Gut (2019)

We appreciate the thoughtful feedback and points raised by authors Moulton, Norton, Powell, Mohamedali and Hopkins regarding the temporality between depression and inflammatory bowel disease (IBD) diagnosis and recommendation to perform further sensitivity analyses.1 The authors correctly highlight that the prodromal effects of IBD, including fatigue and low mood, prior to diagnosis may mimic depression and therefore put temporality into question.2 Furthermore, the median time from Crohn’s disease symptom presentation to diagnosis is 9 months and 75% of patients are diagnosed within 2 years.3 In response, we have performed two sensitivity analyses restricting to observations with at least (1) 9 months between depression and IBD diagnosis and …
Infusion Needle Radiofrequency Ablation for Treatment of Refractory Ventricular Arrhythmias
Authors: William G. Stevenson, Usha B. Tedrow, Vivek Reddy, Amir AbdelWahab, Srinivas Dukkipati, Roy M. John, Akira Fujii, Benjamin Schaeffer, Shinichi Tanigawa, Ihab Elsokkari, Jacob Koruth, Tomofumi Nakamura, Aditi Naniwadekar, Daniele Ghidoli, Christine Pellegrini, John L. Sapp
Journal: Journal of the American College of Cardiology (2019)

Catheter ablation is effective for eliminating most drug-refractory ventricular arrhythmias (VA). However, a major reason for procedural failure is arrhythmia originating deep within the myocardium where it is inaccessible to conventional endocardial or epicardial approaches. Affected patients have limited therapeutic options.The objective of this study was to assess the safety and outcome of a novel radiofrequency ablation catheter that used an extendable/retractable 27-g needle capable of targeting deep arrhythmia (intramural) substrate.Patients who failed at least one prior catheter ablation procedure for sustained ventricular tachycardia (VT) or nonsustained VA with associated left ventricular dysfunction were enrolled at 3 centers. The target was sustained monomorphic VT in 26 patients, including 8 with recent VT storm or VT requiring intravenous medication, and 5 with incessant VA associated with ventricular dysfunction.Needle ablation was performed in 31 patients (median of 2 failed prior ablation procedures; 71% nonischemic heart disease). After a median of 15 needle lesions/patient, ablation abolished at least 1 inducible VT in 19 of 26 VT patients (73%), and suppressed ambient arrhythmia in 4 of 5 nonsustained arrhythmia patients. At the 6-month follow-up, 48% of patients were free of recurrent arrhythmia and another 19% were improved. Procedure-related complications included a single pericardial effusion treated with percutaneous drainage and a left ventricular pacing lead dislodgement with no deaths.In patients with recurrent ventricular arrhythmias refractory to medications and conventional catheter ablation, intramural needle radiofrequency ablation offers significant arrhythmia control with an acceptable procedural risk.
A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy
Authors: Benedicte Sjo Tislevoll, Oda Helen Eck Fagerholt, Nello Blaser, Monica Hellesøy, Stein-Erik Gullaksen, Pilar Ayuda Duran, Laure Isabelle Piechaczyk, Dagim Tadele, Jørn Skavland, Sonia Gavasso, Jorrit Enserink, Yngvar Fløisand, Bjorn Gjertsen
Journal: Blood (2018)
An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma
Authors: Tengteng Yu, Lijie Xing, Liang Lin, Jiye Liu, Kenneth Wen, Shih-Feng Cho, Phillip Hsieh, James Myette, Bharat Chaganty, Hedy Adari, Hamid Tissire, Ketan Deotale, Zach Shriver, Nikhil Munshi, Yu-Tzu Tai, Kenneth Anderson
Journal: Blood (2018)
Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial
Authors: Richard Kajubi, Teddy Ochieng, Abel Kakuru, Prasanna Jagannathan, Miriam Nakalembe, Theodore Ruel, Bishop Opira, Harriet Ochokoru, John Ategeka, Patience Nayebare, Tamara D Clark, Diane V Havlir, Moses R Kamya, Grant Dorsey
Journal: The Lancet (2019)
Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse
Authors: Sandrine Loron, Mohamad Sobh, Fiorenza Barraco, Xavier Thomas, Sophie Ducastelle, Myriam Renault, Florence Ader, Emilie Frobert, Franck-Emmanuel Nicolini, Hélène Labussière, Mauricette Michallet
Journal: Blood (2018)
A Weaning Reaction to Microbiota Is Required for Resistance to Immunopathologies in the Adult
Authors: Ziad Al Nabhani, Sophie Dulauroy, Rute Marques, Clara Cousu, Shahed Al Bounny, François Déjardin, Tim Sparwasser, Marion Bérard, Nadine Cerf-Bensussan, Gérard Eberl
Journal: Immunity (2019)
Abstract 17680: Dyspnoea and Psychological Distress are Associated With Sleep Quality Over Time in Pulmonary Hypertension
Authors: Christi Deaton, Iain Armstrong, Linda McGowan, Paul Sephton, Janelle Yorke
Journal: Circulation (2016)

Pulmonary hypertension (PH) is a debilitating condition characterised by progressive fatigue, dyspnoea, and decreased functional capacity. Poor sleep quality has been reported in cross-sectional st...
Tumor Chemo-Radiotherapy with Rod-Shaped and Spherical Gold Nano Probes: Shape and Active Targeting Both Matter
Authors: Lu Zhang, Huilan Su, Haolu Wang, Qian Li, Xiao Li, Chuanqing Zhou, Jia Xu, Yimin Chai, Xiaowen Liang, Liqin Xiong, Chunfu Zhang
Journal: Theranostics (2019)

The morphologies of gold nanoparticles (NPs) affect their tumor accumulation through enhanced permeability and retention effect. However, detailed information and mechanisms of NPs' characteristics affecting tumor accumulation are limited. The aim of this study is to evaluate the effects of shape and active targeting ligands of theranostic NPs on tumor accumulation and therapeutic efficacy, and to elucidate the underlying mechanism. Methods:αvβ3 integrin-targeted, cisplatin-loaded and radioisotope iodine-125 labeled spherical and rod-shaped gold nano theranostic probes (RGD-125IPt-AuNPs and RGD-125IPt-AuNRs) with similar sizes were fabricated and characterized. The in vivo distribution and chemo-radio therapeutic efficacy against tumors of these newly developed probes were subsequently evaluated. Moreover, a physiologically based pharmacokinetic (PBPK) model was developed to characterize the in vivo kinetics of these probes at the sub-organ level, and to reveal the mechanism of NPs' shape and active targeting ligands effects on tumor accumulation. Result: Cisplatin and iodine-125 were loaded sequentially onto the NPs through a thin polydopamine coating layer on the NPs. Both RGD-125IPt-AuNPs and RGD-125IPt-AuNRs exhibited high specificity for αvβ3 in vitro, with the rod-shaped probe being more efficient. The PBPK model revealed that rod-shaped gold NPs diffused more rapidly in tumor interstitial than the spherical ones. Tumor accumulations of non-targeted and rod-shaped RAD-125IPt-AuNRs was higher in short term (1 h post injection), but not pronounced and similar to that of non-targeted spherical RAD-125IPt-AuNPs in 24 h after intravenous injection, revealing that the NPs' shape did not have a significant impact on tumor accumulations through enhanced permeability and retention (EPR) effect in long-term. While for actively targeted NPs, in addition to a higher distribution coefficient, RGD-125IPt-AuNRs also had a much higher tumor maximum uptake rate constant than RGD-125IPt-AuNPs, indicating both the shape and active targeting ligands affected the tumor uptake of rod-shaped NPs. As a result, RGD-125IPt-AuNRs had a more effective inhibition of tumor growth than RGD-125IPt-AuNPs by chemo-radiationtherapy. Conclusion: Our study suggests that both the shape and active targeting ligands of gold NPs play important roles on tumor accumulation and chemo-radio therapeutic effect.
Prevalence and Severity of Rationing During Drug Shortages
Authors: Andrew Hantel, Mark Siegler, Fay Hlubocky, Kevin Colgan, Christopher K. Daugherty
Journal: JAMA Internal Medicine (2019)

The study by Kesselheim et al, 1 about physicians' perspectives on US Food and Drug Administration (FDA) approval standards and off-label drug marketing, calls attention to the importance of medical evidence and drug safety, issues that were central to Schwartz's research and advocacy.The study found that most physicians oppose any weakening of FDA approval standards and support the agency's current restrictions on off-label marketing. 1Most of the survey respondents thought it would be a "bad" or "terrible" idea for the agency to allow off-label promotion by sales representatives in physicians' offices, drug advertisements in medical journals, or direct-to-consumer advertisements.The clarity of the wording in the survey is typical of Lisa's work.Among many other activities, Lisa and Steve ran courses for journalists, training them to be appropriately skeptical about purported medical breakthroughs, and to better communicate the benefits and harms of medical tests and treatments.Through their work, Schwartz and Woloshin charted a course for physicians and patients to move forward, with less waste and harm through overdiagnosis and overtreatment, less hype about medications that offer no meaningful benefits, and more use of effective care.As they noted in a recent essay, "asking 'Is less more?' has resulted in a profound shift in the ethos of medicine: a recognition that health care truly is a doubleedged sword that can harm as well as benefit patients." 3 We are reminded of why we become physicians, and of the work that remains to be done.Medicine and the world have suffered a great loss with Lisa's untimely death.We will all miss her terribly as we seek to carry on her legacy.
Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies
Authors: Glenn N. Levine, Patrick T. O’Gara, Joshua A. Beckman, Sana M. Al-Khatib, Kim K. Birtcher, Joaquin E. Cigarroa, Lisa de las Fuentes, Anita Deswal, Lee A. Fleisher, Federico Gentile, Zachary D. Goldberger, Mark A. Hlatky, José A. Joglar, Mariann R. Piano, Duminda N. Wijeysundera
Journal: Journal of the American College of Cardiology (2019)